soul trial oral semaglutide cardiovascular outcomes 2024 results Reduces CV Events in T2DM – (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine 🧪 T2DM + ASCVD/CKD 💊 Oral semaglutide 14 mg vs placebo 📉 Projected reduction in major adverse

This approach reflects the success seen with SGLT2 inhibitors, which have demonstrated significant cardioprotective and anti-inflammatory effects in conditions such as SLE, leading to their integration into clinical practice for autoimmune diseases ( Statements Author contributions GC: Conceptualization, Data curation, Investigation, Methodology, Writing original draft, Writing review & editing

[DOI] [PubMed] [Google Scholar] 720.Parkinson J.R., Chaudhri O.B., Kuo Y.T., Field B.C., Herlihy A.H., Dhillo W.S

Cherta-Murillo A, Lett AM, Frampton J, Chambers ES, Finnigan TJA, Frost GS

Some require attention

So all four of these are almost like molecular sponges for your mitochondria

Our citys weather actually helps plan your treatment better